ARHGEF10L

Across TCGA pan-cancer cohorts, ARHGEF10L mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ARHGEF10L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ARHGEF10L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARHGEF10L is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where ARHGEF10L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF10L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	−0.550	<.001	12	view →
HNSC	Male	IV	−1.052	<.001	11	view →
LSCC	Male	II,III,IV	−0.486	<.001	8	view →
LUAD	Male	III,IV	−0.438	<.001	8	view →
PDAC	Female	II,III,IV	−0.901	<.001	6	view →
COAD	All	II,III,IV	−0.120	.003	4	view →
OV	All	All	−0.829	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ARHGEF10L–CCRCC

Open the CCRCC breakdown →